IFM Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees
  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $55.5M

  • Investors
  • 2

IFM Therapeutics General Information

Description

Developer of small molecule medicines designed to transform immunotherapy. The company's medicines precisely target the innate immune system to solve challenging problems in the treatment of inflammatory and autoimmune disorders and cancer, and to improve immune response in patients, enabling medical practitioners to improve the lives of patients with serious diseases.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Parent Company
Primary Office
  • 855 Boylston Street
  • 11th Floor
  • Boston, MA 02116
  • United States
+1 (857) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IFM Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 02-Dec-2019 $55.5M 000.00 Completed Clinical Trials - General
3. Merger/Acquisition 06-Sep-2017 00.00 0000 00.00 Completed Clinical Trials - General
2. Early Stage VC (Series A) 22-Jun-2016 $27M $27M 0000 Completed Clinical Trials - General
1. Accelerator/Incubator 24-Jul-2015 Completed Clinical Trials - General
To view IFM Therapeutics’s complete valuation and funding history, request access »

IFM Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 0,000,000 00.000000 00 000.0 000.0 00 000.0 000
Series A1 000,000 00.000000 00 00 00 00 00 00.00
To view IFM Therapeutics’s complete cap table history, request access »

IFM Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of small molecule medicines designed to transform immunotherapy. The company's medicines precisely target the
Drug Discovery
Boston, MA
20 As of 2022
000.00
0000000000 0 000.00

000000

si ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit ess
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00

00000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IFM Therapeutics Competitors (53)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
00000 000000000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000 000000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000000 00000
000000000000 00000 Formerly VC-backed Jerusalem, Israel 00 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
You’re viewing 5 of 53 competitors. Get the full list »

IFM Therapeutics Executive Team (14)

Name Title Board Seat Contact Info
H. Martin Seidel Ph.D Chief Executive Officer & Board Member
Dennis Dean Ph.D Chief Development Officer
Eicke Latz MD Co-Founder, Scientific Advisor & Consultant
Matthias Geyer Ph.D Co-Founder & Scientific Advisor
Gary Glick Ph.D Co-Founder & Executive Chairman
You’re viewing 5 of 14 executive team members. Get the full list »

IFM Therapeutics Board Members (9)

Name Representing Role Since
Gary Glick Ph.D IFM Therapeutics Co-Founder & Executive Chairman 000 0000
H. Martin Seidel Ph.D IFM Therapeutics Chief Executive Officer & Board Member 000 0000
Jean-Francois Formela MD Self Board Member & Partner 000 0000
John Leonard MD Self Board Member 000 0000
Michael Gladstone Atlas Venture Board Observer 000 0000
You’re viewing 5 of 9 board members. Get the full list »

IFM Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IFM Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Venture Capital Minority 000 0000 000000 0
Novartis Corporation Minority 000 0000 000000 0
To view IFM Therapeutics’s complete investors history, request access »